ストックスクリーナーアプリを入手
18.71
3.56%
-0.675
前日終値:
$19.39
開ける：
$19.29
24時間の取引高:
412.01K
Relative Volume:
0.24
時価総額：
$1.90B
収益：
$54.55M
当期純損益:
$-193.57M
株価収益率:
-6.4758
EPS:
-2.89
ネットキャッシュフロー:
$-181.86M
1週間 パフォーマンス:
-2.65%
1か月 パフォーマンス:
-3.06%
6か月 パフォーマンス:
+60.79%
1年 パフォーマンス:
-6.31%
1日の値動き範囲:
$18.65
$19.57
1週間の範囲:
$18.11
$20.18
52週間の値動き範囲:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
名前
Nurix Therapeutics Inc
セクター
電話
(415) 660-5320
住所
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
18.70 | 1.97B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.65 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-03-17 | 開始されました | Leerink Partners | Market Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-11 | 開始されました | Jefferies | Buy |
| 2024-09-06 | 再開されました | Robert W. Baird | Outperform |
| 2024-07-31 | 開始されました | Truist | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-09 | 開始されました | Barclays | Overweight |
| 2023-02-28 | 開始されました | Oppenheimer | Outperform |
| 2022-10-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-12-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-30 | 再開されました | Piper Sandler | Overweight |
| 2021-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-11-19 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | Stifel | Buy |
すべてを表示
Nurix Therapeutics Inc (NRIX) 最新ニュース
Nurix Therapeutics chief legal officer Ring sells $69,273 in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics chief legal officer Ring sells $69,273 in stock - Investing.com
Nurix Therapeutics (NRIX) to Release Earnings on Tuesday - MarketBeat
Market Rankings: What is the next catalyst for Nurix Therapeutics IncJuly 2025 Price Swings & Verified Swing Trading Watchlists - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know - sharewise.com
Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX) - Seeking Alpha
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - The AI Journal
Aug Fed Impact: Is Contango Ore Inc attractive for institutional investorsJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - baoquankhu1.vn
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
BTIG reiterates Buy rating on Nurix stock with $30 price target - Investing.com UK
Sectors Review: Is Nurix Therapeutics Inc a stock for growth or value investorsJuly 2025 Movers & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Volume Summary: Why Nurix Therapeutics Inc. stock could outperform in 2025 - Bộ Nội Vụ
Nurix outlines 2026 strategy for BTK degrader bexobrutideg in pivotal trials - Investing.com Nigeria
Do Analyst Upgrades Clarify Nurix Therapeutics’ (NRIX) True Potential Or Complicate Its Valuation Story? - Sahm
NRIX: Bexabrutadeg shows best-in-class potential in CLL, driving pivotal trials and pipeline expansion - TradingView — Track All Markets
Nurix Therapeutics, Inc. Outlines 2026 Goals and Objectives - TradingView — Track All Markets
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - Investing News Network
Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside (NASDAQ:NRIX) - Seeking Alpha
Inside Nurix's push to test a new cancer and autoimmune drug in 2026 - Stock Titan
Published on: 2026-01-10 21:09:42 - ulpravda.ru
Why retail investors pile into Nurix Therapeutics Inc. stockEarnings Growth Report & Fast Entry and Exit Trade Plans - ulpravda.ru
Aug Patterns: Why Nurix Therapeutics Inc. stock appeals to analystsPortfolio Gains Summary & Daily Stock Momentum Reports - Улправда
How Nurix Therapeutics Inc. stock compares to market leadersPortfolio Profit Report & Low Risk Entry Point Guides - ulpravda.ru
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Exploring a 59% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
What 18 Analyst Ratings Have To Say About Nurix Therapeutics - Sahm
Morgan Stanley Upgrades Nurix Therapeutics (NRIX) - Nasdaq
Dow Theory LettersNurix Therapeutics, Inc.Common stock (Nasdaq:NRIX) Detailed Stock Data - FinancialContent
Will Nurix Therapeutics Inc. stock beat EPS estimates2025 Major Catalysts & Precise Swing Trade Entry Alerts - Улправда
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpStill a Buy? - MarketBeat
NRIX: Morgan Stanley Upgrades Nurix Therapeutics with a Raised P - GuruFocus
Should I hold or sell Nurix Therapeutics Inc. stock in 20252026 world cup usa national team round of 32 goalkeepers high defensive line winner prediction statistical analysis - ulpravda.ru
User | ricentral.comNurix Therapeutics, Inc.Common stock (Nasdaq:NRIX) Stock Quote - FinancialContent
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Nurix Therapeutics Inc Stock Analysis and ForecastMarket Sentiment Extremes & High-Risk, High-Reward? We Find the Winners - earlytimes.in
NRIX Stock Price, Forecast & Analysis | NURIX THERAPEUTICS INC (NASDAQ:NRIX) - Chartmill
Trading Systems Reacting to (NRIX) Volatility - Stock Traders Daily
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is It Too Late to Sell Shiva Texyarn LimitedTechnical Breakout Signals & Discover Top Gainers in Every Sector - earlytimes.in
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
(NRIX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Certain Pre-funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025. - marketscreener.com
Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics’ Degrader Platform (NRIX)? - Yahoo Finance
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT - Insider Monkey
Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge - Yahoo Finance
Stock Analysis: Is Nurix Therapeutics Inc. stock a defensive play in 2025Quarterly Performance Summary & AI Forecasted Entry and Exit Points - Улправда
Nurix Therapeutics Inc (NRIX) 財務データ
収益
当期純利益
現金流量
EPS
4.38%
1.95%
大文字化:
|
ボリューム (24 時間):